DR. GERALD SMALDONE, M.D.
Osteopathic Medicine at Research Way, Strongs Neck, NY
License number
New York 142684
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
2
26 Research Way, Strongs Neck, NY 11733
PO Box 1559, Stonybrook, NY 11790
PO Box 1559, Stonybrook, NY 11790
Phone
(631) 444-0580
Personal information
See more information about GERALD SMALDONE at radaris.comName
Address
Phone
47 Main St, East Setauket, NY 11733
47 Main St, East Setauket, NY 11733
4 Cutchogue Ct, Ridge, NY 11961
Organization information
See more information about GERALD SMALDONE at bizstanding.comGerald Smaldone MD,PHD
26 Research Way, East Setauket, NY 11733
Industry:
Pulmonologist, Internist, Obgyn
Phone:
(631) 444-1750 (Phone)
Gerald Christopher Smaldone
Gerald Smaldone MD
100 Nicolls Rd, Stonybrook, NY 11794
Categories:
Pulmonary & Respiratory Physicians & Surgeons
Phone:
(631) 444-1750 (Phone)
Professional information
Gerald Christopher Smaldone, East Setauket NY
Specialties:
Internal Medicine, Critical Care Medicine, Pulmonary Disease, Critical Care Medicine
Work:
Stony Brook Internists
26 Research Way, East Setauket, NY 11733 Stony Brook Specialists/Sb Internists
3001 Expressway Dr N, Islandia, NY 11749
26 Research Way, East Setauket, NY 11733 Stony Brook Specialists/Sb Internists
3001 Expressway Dr N, Islandia, NY 11749
Education:
New York University (1975)
Methods, Devices And Formulations For Targeted Endobronchial Therapy
US Patent:
8261747, Sep 11, 2012
Filed:
Apr 25, 2005
Appl. No.:
10/999788
Inventors:
Gerald C. Smaldone - Setauket NY, US
Lucy B. Palmer - Nissequogue NY, US
Lucy B. Palmer - Nissequogue NY, US
Assignee:
The Research Foundation of State University of New York - Albany NY
International Classification:
A61M 16/00, A61M 11/00, A61M 15/00, A61M 16/10, A62B 9/06
US Classification:
12820714, 12820014, 12820312
Abstract:
The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.
Methods, Devices And Formulations For Targeted Endobronchial Therapy
US Patent:
8602023, Dec 10, 2013
Filed:
Feb 22, 2005
Appl. No.:
11/062519
Inventors:
Gerald C. Smaldone - Setauket NY, US
Lucy B. Palmer - Nissequogue NY, US
Lucy B. Palmer - Nissequogue NY, US
Assignee:
The Research Foundation for the State University of New York - Albany NY
International Classification:
A61M 11/00, A61M 16/10
US Classification:
12820315, 12820014, 12820024, 12820312
Abstract:
The invention provides improved devices for treating tracheobronchitis, bronchiectasis and pneumonia in intubated patients, with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment, the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The devices eliminate the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment also concentrates the therapeutic agent at affected sites in the lung such that therapeutic levels of administrated drug are achieved without systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this regimen.
Medthods, Devices And Formulations For Targeted Endobronchial Therapy
US Patent:
2010004, Feb 18, 2010
Filed:
Aug 24, 2009
Appl. No.:
12/546260
Inventors:
Gerald C. Smaldone - Setauket NY, US
Lucy B. Palmer - Nissequogue NY, US
Lucy B. Palmer - Nissequogue NY, US
International Classification:
A61K 31/137, A61M 11/00, A61P 11/06, A61P 31/04, A61P 11/08
US Classification:
514653, 12820023
Abstract:
The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.
Method Of Treating Pulmonary Disease With Interferons
US Patent:
2012014, Jun 14, 2012
Filed:
Feb 3, 2009
Appl. No.:
12/322440
Inventors:
Rany Condos - Bechurst NY, US
Gerald C. Smaldone - Setauket NY, US
Gerald C. Smaldone - Setauket NY, US
International Classification:
A61K 38/21, A61P 11/00
US Classification:
424 855, 424 856, 424 857
Abstract:
A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.
Method Of Treating Tuberculosis With Interferons
US Patent:
2012021, Aug 30, 2012
Filed:
Dec 20, 2011
Appl. No.:
13/374273
Inventors:
Rany Condos - Bechurst NY, US
Gerald Smaldone - Setauket NY, US
Gerald Smaldone - Setauket NY, US
International Classification:
A61K 38/21, A61P 31/06, C07K 14/565, C07K 14/57, C07K 14/555, C07K 14/56
US Classification:
424 855, 424 854, 424 857, 424 856, 530351
Abstract:
A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.
Face Mask For Use In Pressurized Drug Delivery Systems
US Patent:
7082947, Aug 1, 2006
Filed:
Oct 28, 2004
Appl. No.:
10/978068
Inventors:
Gerald C. Smaldone - Setauket NY, US
International Classification:
A62B 18/08, A62B 18/02
US Classification:
12820623, 12820621, 12820626, 12820628
Abstract:
Face masks for use in pressurized drug delivery applications, such as aerosol drug delivery systems, and a method of reducing aerosol deposition in the region of the eyes are presented. The face masks according to the various embodiments disclosed herein contain features that reduce the inertia of the aerosolized drug in perinasal areas. This results in a reduction in the amount of aerosolized drug that is deposited in the region of the eyes by inertial impaction, while at the same time, the features are constructed to maintain the flow of the aerosolized drug into the face mask so that the aerosolized drug is effectively delivered to the respiratory system of the patient.
Method Of Treating Pulmonary Disease With Interferons
US Patent:
2011005, Mar 10, 2011
Filed:
Jan 6, 2010
Appl. No.:
12/655709
Inventors:
Rany Condos - Bechurst NY, US
Gerald C. Smaldone - Setauket NY, US
Gerald C. Smaldone - Setauket NY, US
International Classification:
A61K 38/21, A61P 11/00, A61P 11/06
US Classification:
424 855, 424 854, 424 857, 424 856
Abstract:
A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.
Method Of Treating Pulmonary Disease With Interferons
US Patent:
8486383, Jul 16, 2013
Filed:
Dec 21, 2011
Appl. No.:
13/374308
Inventors:
Gerald Smaldone - Setauket NY, US
Rany Condos - Beechurst NY, US
Rany Condos - Beechurst NY, US
Assignee:
New York University - New York NY
The Research Foundation of the State University of New York - Stony Brook NY
The Research Foundation of the State University of New York - Stony Brook NY
International Classification:
A61K 38/00, A61K 38/21, C07K 14/00
US Classification:
424 855, 424 854, 514 15, 514 212, 530351
Abstract:
A method of treating a pulmonary disease such as, for instance idiopathic pulmonary fibrosis (IPF), mixed connective tissue disease and asthma, comprising administering an aerosolized interferon such as interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) alone or in combination with other therapeutic agents are provided.
Method Of Treating Idiopathic Pulmonary Fibrosis With Aerosolized Ifn-Γ
US Patent:
6964761, Nov 15, 2005
Filed:
Dec 12, 2002
Appl. No.:
10/318352
Inventors:
Rany Condos - Beechurst NY, US
William Rom - Rye NY, US
Gerald Smaldone - Setauket NY, US
William Rom - Rye NY, US
Gerald Smaldone - Setauket NY, US
Assignee:
New York University - New York NY
The Research Foundation of the State University of New York - Stony Brook NY
The Research Foundation of the State University of New York - Stony Brook NY
International Classification:
A61K038/21, A61K045/00, C07K017/00
US Classification:
424 855, 424 854, 530351
Abstract:
A method of treating idiophathic pulmonary fibrosis (IPF), comprising administering aerosolized interferon-γ in a therapeutically effective amount to achieve improved or ameliorated symptoms of IPF.